GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

About this update from Gensight Biologics Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/f4cc160f214d9b8d489a5e4b22296bf3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4o.C8i711FBn8MJsJ67.fQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwOA--/https://media.zenfs.com/en/business-wire.com/f4cc160f214d9b8d489a5e4b22296bf3","width":480,"height":204},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_Z8wn0SnSjWipwB0PAMupw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI3Mg--/https://media.zenfs.com/en/business-wire.com/f4cc160f214d9b8d489a5e4b22296bf3","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, May 11, 2026--(BUSINESS WIRE)--Regulatory News:","length":54,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.","length":647,"tagName":"p"},{"type":"text","content":"The full article, named "Efficacy of lenadogene nolparvovec gene therapy versus idebenone in Leber hereditary optic neuropathy due to the m.11778G>A MT- ND4 variant: two matching adjusted indirect comparisons", is available online on this link.","length":257,"tagName":"p"},{"type":"text","content":"About GenSight Biologics","length":24,"tagName":"p"},{"type":"text","content":"GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ ...

More updates from Gensight Biologics Sa